BioSpace News Archive

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2020.

MOBILion Systems, Inc. is partnering with Drs. Lance Wells and Michael Tiemeyer, pioneering researchers at the Complex Carbohydrate Research Center, University of Georgia, to conduct COVID-19 glycan analysis using the company’s patented SLIM separations technology..

Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, is announcing the launch of the OASIS Study.

Healthcare Trust of America, Inc. (NYSE: HTA), the largest dedicated owner and operator of medical office buildings in the United States, announced today that on Tuesday, May 5, 2020, after the market closes, HTA will report its financial results for the three months ending March 31, 2020.

Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that the Company has entered into a research collaboration with the Fraunhofer Institute for Cell Therapy and Immunology (IZI) and acquired related patents from the Institute for a meprin protease inhibitor and assay platform.

For more detail related to the fiscal year 2020 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02)

VALBIOTIS, a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its results for the 2019 fiscal year and reviews its recent milestone achievements.

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)

Two Israeli hospitals deploy Tamar’s non-invasive ventilation (NIV) hood, The Greenhouse, which is available for Hospital Systems and Staff around the world